After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The move follows promising but early data presented at ASCO.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
